Skip to content

Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes

Strict Versus Permissive Threshold for Initiation of Pharmacotherapy in Gestational Diabetes Mellitus (GDM) With Glucometer Use - A Randomized Control Trial (START1)

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06419777
Acronym
START 1
Enrollment
430
Registered
2024-05-17
Start date
2024-09-01
Completion date
2026-05-31
Last updated
2024-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gestational Diabetes, Pregnancy Related

Keywords

gestational diabetes, pregnancy, insulin, Initiation of medication

Brief summary

The aim of our study is to compare neonatal and maternal outcomes using different thresholds for the initiation and titration of pharmacotherapy for gestational diabetes (GDM). Our goal is to compare a strict and permissive threshold. The strict threshold is defined as two abnormal values or more over a one-week period (two fasting values elevated, two of the same post prandial values elevated, or 1 fasting and 1 post prandial value elevated), whereas the permissive threshold is defined as 50% of values elevated over 1 week (50% of overall fasting values, 50% of postprandial values, or 50% of overall values).

Detailed description

Pregnancy is a state of insulin resistance to ensure that the growing fetus has ample nutrition. Gestational Diabetes (GDM) develops in pregnant patients with pancreatic dysfunction that leads to impairment of glucose tolerance. Various studies have examined the benefit of treatment for GDM, including the 2005 Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS) and the 2009 Landon et al randomized controlled trials. These studies found that treatment was associated with a significant reduction in newborn complications of perinatal death, shoulder dystocia, large for gestational age infants, cesarean delivery, and birth trauma. The specific threshold value for initiation and up-titration of medical therapy is unknown. Lack of evidence leads to a wide variation in clinical practice of pharmacological initiation and titration for GDM. A systematic review and meta-analysis by Caissutti in 2019 analyzed criteria for initiating pharmacotherapy for GDM and noted the following: 12 of 15 trials initiated pharmacotherapy after 1-2 abnormal values over 1-2 weeks, 2 studies initiated pharmacotherapy after 50% of overall values were abnormal, and 1 study initiated pharmacotherapy after 30% of overall values were abnormal. However, there have been no randomized controlled trials of head-to-head comparison of different thresholds. The aim of our study is to compare neonatal and maternal outcomes using different thresholds for the initiation and titration of pharmacotherapy for gestational diabetes. Our goal is to compare a strict and relaxed threshold. The strict threshold is defined as two abnormal values or more over a one week period (two fasting values elevated, two of the same post prandial values elevated, or 1 fasting and 1 post prandial value elevated), whereas the relaxed threshold is defined as 50% of values elevated over 1 week (50% of overall fasting values, 50% of postprandial values, or 50% of overall values).

Interventions

DRUGInsulin

Insulin will be used in gestational diabetics to control blood glucose levels

Sponsors

University of Rochester
CollaboratorOTHER
Thomas Jefferson University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Live, non-anomalous fetus * Literacy in English, Spanish, Mandarin, or Arabic * Patients are also required to provide consent, demonstrate an understanding of the purpose of the study, and agree to the study protocol.

Exclusion criteria

* \<18 years at EDD * pre-existing diabetes or diagnosis of GDM before 24 weeks * multi-fetal gestation * known major fetal anomaly * known allergy to insulin * chronic maternal corticosteroid use * diagnosis of GDM based on finger sticks alone * patients who have contraindication to oral glucose tolerance test * a primary language other than English, Spanish, Mandarin, or Arabic

Design outcomes

Primary

MeasureTime frameDescription
Neonatal Composite OutcomeFirst 28 days of birthneonatal composite including the following measures: large for gestational age (LGA) of neonate defined as birth weight \>90th percentile for gestational age using the Fenton growth chart, hypoglycemia o defined as glucose \<40 mg/dL \<48 hours after birth or glucose, hyperbilirubinemia, stillbirth or neonatal death, birth trauma

Secondary

MeasureTime frameDescription
Neonatal Outcome: APGAR ScoreAt 1 minute of life and at 5 min of lifeScoring system provided a standardized assessment for infants after delivery from 0-10
Neonatal Outcome: BirthweightDelivery TimeBirthweight in grams, Macrosomia (birthweight \>4000g, Small for gestational age (\<10th percentile based on Fenton Growth Charts)
Neonatal Outcome: Brachial Plexus InjuryDelivery TimeBrachial plexus nerves in neonate are torn, stretched, or compressed at delivery
Neonatal Outcome: Respiratory distressWithin first 24 hours after deliveryBreathing difficulties after birth requiring supplemental oxygen, mask, intubation, and/or surfactant
Neonatal Outcome: Admission to Neonatal intensive Care UnitFrom delivery to discharge from NICUAdmission to neonatal intensive care unit (NICU)
Maternal Outcomes: Maternal hypoglycemiaInitiation of insulin to deliveryMaternal episode of hypoglycemia \< 60 mg/dL throughout the pregnancy
Neonatal Outcome: Gestational Age of BirthDelivery TimeGestational age at delivery in weeks and days
Maternal Outcomes: Obstetric anal sphincter injury (OASIS)At Delivery3rd degree and 4th degree perineal injuries
Maternal Outcomes: Operative DeliveryAt DeliveryVacuum-assisted and Forcep-assisted vaginal Delivery
Maternal Outcomes: Cesarean DeliveryAt DeliveryCesarean birth
Maternal Outcomes: Postpartum hemorrhageWithin 24 hours of deliveryDefined as cumulative blood loss ≥1000 mL, or bleeding associated with signs/symptoms of hypovolemia within 24 hours of the birth process
Maternal Outcomes: Hypertensive Disorders of PregnancyFrom gestational age of 20 weeks during pregnancy to 6 weeks postpartumHypertensive disorders of pregnancy: gestational hypertension, Preeclampsia without severe features, Pre-eclampsia with severe features, severe range blood pressures defined as (systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥110 mmHg), symptoms of central nervous dysfunction, thrombocytopenia with Platelet count \<100,000 platelets/microL, hepatic abnormalities, kidney impairment, and or pulmonary edema
Maternal Outcomes: Shoulder DystociaAt DeliveryAn obstetric emergency where the anterior fetal shoulder becomes stuck on the maternal pubic symphysis, delaying the birth of the baby's body.

Countries

United States

Contacts

Primary ContactKavisha Khanuja, MD
kxk334@jefferson.edu215-955-5000
Backup ContactRodney McLaren Jr, MD
rodney.mclaren@jefferson.edu215-955-5000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026